Astrid Gesper

Dr. Astrid Gesper

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2017 in Nanoscale
Verified
Journal Article
Closed access
PDF file
AGAstrid Gesper
Astrid Gesper
PHPhilipp Hagemann
Philipp Hagemann
PHPatrick Happel
Patrick Happel
We present an improved Scanning Ion Conductance Microscope that allows high-resolution studies of the interaction of nanoparticles and the cell membrane.

15 January 2024 in Glycobiology
Verified
Journal Article
Open access
PDF file
CNCarolin T Neu
Carolin T Neu
LWLinus Weilepp
Linus Weilepp
KBKaya Bork
Kaya Bork
AGAstrid Gesper
Astrid Gesper
RHRüdiger Horstkorte
Rüdiger Horstkorte
GNE myopathy (GNEM) is a late-onset muscle atrophy, caused by mutations in the gene for the key enzyme of sialic acid biosynthesis, UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase (GNE). With an incidence of one to nine cases per million it is an ultra-rare, so far untreatable, autosomal recessive disease. Several attempts have been made to treat GNEM patients by oral supplementation with sialic acid precursors (e.g. N-acetylmannosamine, ManNAc) to restore sarcolemmal sialylation and muscle strength. In most studies, however, no significant improvement was observed. The lack of a suitable mouse model makes it difficult to understand the exact pathomechanism of GNEM and many years of research have failed to identify the role of GNE in skeletal muscle due to the lack of appropriate tools. We established a CRISPR/Cas9-mediated Gne-knockout cell line using murine C2C12 cells to gain insight into the actual role of the GNE enzyme and sialylation in a muscular context. The main aspect of this study was to evaluate the therapeutic potential of ManNAc and N-acetylneuraminic acid (Neu5Ac). Treatment of Gne-deficient C2C12 cells with Neu5Ac, but not with ManNAc, showed a restoration of the sialylation level back to wild type levels–albeit only with long-term treatment, which could explain the rather low therapeutic potential. We furthermore highlight the importance of sialic acids on myogenesis, for C2C12 Gne-knockout myoblasts lack the ability to differentiate into mature myotubes.

24 November 2023 in Frontiers in Bioscience-Landmark
Verified
Journal Article
Open access
PDF file
EPEmilia Peters
Emilia Peters
PSPhilipp Selke
Philipp Selke
KBKaya Bork
Kaya Bork
RHRüdiger Horstkorte
Rüdiger Horstkorte
AGAstrid Gesper
Astrid Gesper
Background: A key mechanism in the neuromuscular disease GNE myopathy (GNEM) is believed to be that point mutations in the GNE gene impair sialic acid synthesis – maybe due to UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase (GNE) activity restrictions – and resulting in muscle tissue loss. N-acetylmannosamine (ManNAc) is the first product of the bifunctional GNE enzyme and can therefore be regarded as a precursor of sialic acids. This study investigates whether this is also a suitable substance for restoring the sialic acid content in GNE-deficient cells. Methods: A HEK-293 GNE-knockout cell line was generated using CRISPR-Cas9 and analyzed for its ability to synthesize sialic acids. The cells were then supplemented with ManNAc to compensate for possible GNE inactivity and thereby restore sialic acid synthesis. Sialic acid levels were monitored by immunoblot and high performance liquid chromatography (HPLC). Results: The HEK-293 GNE-knockout cells showed almost no polysialylation signal (immunoblot) and a reduced overall (–71%) N-acetylneuraminic acid (Neu5Ac) level (HPLC) relative to total protein and normalized to wild type level. Supplementation of GNE-deficient HEK-293 cells with 2 mM ManNAc can restore polysialylation and free intracellular sialic acid levels to wild type levels. The addition of 1 mM ManNAc is sufficient to restore the membrane-bound sialic acid level. Conclusions: Although the mechanism behind this needs further investigation and although it remains unclear why adding ManNAc to GNE-deficient cells is sufficient to elevate polysialylation back to wild type levels – since this substance is also converted by the GNE, all of this might yet prove helpful in the development of an appropriate therapy for GNEM.

23 February 2023 in Biomolecules
Verified
Journal Article
Open access
PDF file
VHVanessa Hagenhaus
Vanessa Hagenhaus
JLJacob L. Gorenflos López
Jacob L. Gorenflos López
RRRebecca Rosenstengel
Rebecca Rosenstengel
CNCarolin Neu
Carolin Neu
CHChristian P. R. Hackenberger
Christian P. R. Hackenberger
AGAstrid Gesper
Astrid Gesper
Mutations in the gene coding for the bi-functional UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase (GNE), the key enzyme of the sialic acid biosynthesis, are responsible for autosomal-recessive GNE myopathy (GNEM). GNEM is an adult-onset disease with a yet unknown exact pathophysiology. Since the protein appears to work adequately for a certain period of time even though the mutation is already present, other effects appear to influence the onset and progression of the disease. In this study, we want to investigate whether the late onset of GNEM is based on an age-related effect, e.g., the accumulation of post-translational modifications (PTMs). Furthermore, we also want to investigate what effect on the enzyme activity such an accumulation would have. We will particularly focus on glycation, which is a PTM through non-enzymatic reactions between the carbonyl groups (e.g., of methylglyoxal (MGO) or glyoxal (GO)) with amino groups of proteins or other biomolecules. It is already known that the levels of both MGO and GO increase with age. For our investigations, we express each domain of the GNE separately, treat them with one of the glycation agents, and determine their activity. We demonstrate that the enzymatic activity of the N-acetylmannosamine kinase (GNE-kinase domain) decreases dramatically after glycation with MGO or GO—with a remaining activity of 13% ± 5% (5 mM MGO) and 22% ± 4% (5 mM GO). Whereas the activity of the UDP-N-acetylglucosamine 2-epimerase (GNE-epimerase domain) is only slightly reduced after glycation—with a remaining activity of 60% ± 8% (5 mM MGO) and 63% ± 5% (5 mM GO).

19 August 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
PMPaula M. Müller
Paula M. Müller
LWLinus Weilepp
Linus Weilepp
KBKaya Bork
Kaya Bork
RHRüdiger Horstkorte
Rüdiger Horstkorte
AGAstrid Gesper
Astrid Gesper
The crossing of the endothelial cell layer and the glycocalyx that shields it can be considered the final barrier for substances trying to pass from the blood into the surrounding tissue. Due to their terminal position on glycan structures, sialic acids constitute the initial point of contact encountered by invading substances or bacteria. In this study, we investigated the influence of varying sialic acid levels on endothelial cell adhesion and barrier permeability. Furthermore, the successful desialylation as well as the potential for resialylation of two natively sialylated proteins – podocalyxin and integrin beta-1 – were investigated in detail. Desialylation of the cells was achieved either by sialidase-treatment or by knocking out the key enzyme of the sialic acid biosynthesis – the UDP- N -acetylglucosamine 2-epimerase/ N -acetylmannosamine kinase (GNE). We could confirm a sialic acid deficiency after both approaches, which was more pronounced in the GNE -KO cells than in the sialidase-treated cells. Furthermore, a reduced barrier permeability and a negative effect on adhesion were observed. Partial resialylation of GNE -KO cells was achieved either by supplementation with N- acetylmannosamine (ManNAc) or with N- acetylneuraminic acid (Neu5Ac); however, the effects on adhesion and permeability were not fully compensated thereby.